Figure 5.
Survival analysis for nuclear and cytoplasmic MAGE-A6/MAGE-A11 phenotypes. (A-D; Kaplan–Meier analysis). The number of patients in the analyzed groups is as follows: For DSS in N6/11–1 phenotype 49 (censored (C) = 40 and death (D) = 9), N6/11–2: 67 (C = 49 and D = 18), N6/11–3: 21 (C = 19 and D = 2), N6/11–4: 21 (C = 17 and D = 4), C6/11–1: 23 (C = 19 and D = 4), and C6/11–2: 38 (C = 31 and D = 17), C6/11–3 : 22 (C = 16 and D = 6), and C6/11–4: 75 (C = 59 and D = 16). For PFS in N6/11–1 phenotype 49 (C = 37 and D = 12), N6/11–2: 67 (C = 46 and D = 21), N6/11–3: 21 (C = 17 and D = 14), N6/11–4: 21 (C = 16 and D = 5), C6/11–1: 23 (C = 17 and D = 6), and C6/11–2: 38 (C = 30 and D = 8), C6/11–3: 22 (C = 16 and D = 6), and C6/11–4: 75 (C = 53 and D = 22). C: cytoplasmic, C6/11: cytoplasmic expression of MAGE-A6 and MAGE-A11, DSS: disease-specific survival, N: nuclear, N6/11: nuclear expression of MAGE-A6 and MAGE-A11, P: p-value, PFS: progression-free survival, 1: MAGE-A6low/MAGE-A11low phenotype, 2: MAGE-A6low/MAGE-A11high phenotype, 3: MAGE-A6low/MAGE-A11high phenotype, 4: MAGE-A6high/MAGE-A11high phenotype. Charts were drawn by Prism version 8.3.0 software (Graph Pad Inc., San Diego, CA, USA). https://www.graphpad.com/support/faq/prism-830-release-notes/.